The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2019

Filed:

Jul. 31, 2017
Applicant:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Inventors:

Jay Copeland Strum, Hillsborough, NC (US);

John Emerson Bisi, Apex, NC (US);

Patrick Joseph Roberts, Durham, NC (US);

Ricky D. Gaston, Kalamazoo, MI (US);

Robert C. Gadwood, Portage, MI (US);

Assignee:

G1 Therapeutics, Inc., Research Triangle Park, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/14 (2006.01); C07D 487/20 (2006.01); C07D 471/20 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61K 31/527 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/519 (2013.01); A61K 31/527 (2013.01); A61K 45/06 (2013.01); C07D 487/14 (2013.01); C07D 487/20 (2013.01); C07D 471/20 (2013.01);
Abstract

This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.


Find Patent Forward Citations

Loading…